Cargando…

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)

BACKGROUND AND AIMS: Familial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characterized by the formation of abnormal triglyceride- and cholesterol-rich lipoproteins (remnant particles). Patients with FDBL have a high risk for atherosclerotic disease. The effect of PCSK9 inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waldmann, Elisa, Wu, Liya, Busygina, Kristina, Altenhofer, Julia, Henze, Kerstin, Folwaczny, Alexander, Parhofer, Klaus G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942248/ https://www.ncbi.nlm.nih.gov/pubmed/35320320 http://dx.doi.org/10.1371/journal.pone.0265838

Ejemplares similares

Postprandial Lipid Metabolism in Normolipidemic Subjects and Patients with Mild to Moderate Hypertriglyceridemia: Effects of Test Meals Containing Saturated Fatty Acids, Mono-Unsaturated Fatty Acids, or Medium-Chain Fatty Acids
por: Folwaczny, Alexander, et al.
Publicado: (2021)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient Replacement and Time Point of Consumption: A Prospective, Randomized, Controlled Trial
por: Bamberger, Charlotte, et al.
Publicado: (2017)

A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial
por: Bamberger, Charlotte, et al.
Publicado: (2018)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)
por: Pallazola, Vincent A., et al.
Publicado: (2019)

Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol
por: Sampson, Maureen, et al.
Publicado: (2022)

Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
por: Xu, Rui-Xia, et al.
Publicado: (2014)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
por: Dixon, Dave L, et al.
Publicado: (2017)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
por: Zhang, Xiang, et al.
Publicado: (2020)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene
por: Heidemann, Britt E., et al.
Publicado: (2022)

Lipoprotein subfraction patterns throughout gestation in The Gambia: changes in subfraction composition and their relationships with infant birth weights
por: Woo, Jessica G., et al.
Publicado: (2023)

Effect of sleeve gastrectomy on postprandial lipoprotein metabolism in morbidly obese patients
por: Waldmann, Elisa, et al.
Publicado: (2013)

Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile
por: Corey, Kathleen E, et al.
Publicado: (2014)

Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes
por: Kamijo, Yuka, et al.
Publicado: (2019)

Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan
por: Hsu, Hung, et al.
Publicado: (2019)

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
por: Masuda, Daisaku, et al.
Publicado: (2020)

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study
por: Gupta, Milan, et al.
Publicado: (2022)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Intercorrelations of lipoprotein subfractions and their covariation with lifestyle factors in healthy men
por: Parlesak, Alexandr, et al.
Publicado: (2014)

Association between Lipoprotein Subfractions, Hemostatic Potentials, and Coronary Atherosclerosis
por: Poropat Flerin, Tadeja, et al.
Publicado: (2022)

Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study
por: Blokhina, Anastasia V., et al.
Publicado: (2023)

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
por: Toth, Peter P., et al.
Publicado: (2017)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9
por: Choi, Seungbum, et al.
Publicado: (2013)

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches
por: Nikolic, Dragana, et al.
Publicado: (2013)

Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
por: Purmalek, Monica M, et al.
Publicado: (2019)

Subfractional Spectrum of Serum Lipoproteins and Gut Microbiota Composition in Healthy Individuals
por: Kashtanova, Daria A., et al.
Publicado: (2021)

Postprandial Hyperlipidemia and Remnant Lipoproteins
por: Masuda, Daisaku, et al.
Publicado: (2017)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
por: Izkhakov, Elena, et al.
Publicado: (2021)

Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer
por: Flote, Vidar G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p26e5s9v3gsos7mp0d2b8nrnml